Peptides explained
Semaglutide: how it works
Page updated · Sources and editorial approach
A GLP-1 receptor agonist used in specific authorised prescription medicines, with clinical evidence that depends on the product, indication and population.
Semaglutide at a glance
What it does biologically
Activates GLP-1 receptors, a signalling pathway involved in appetite and glucose regulation.
What the evidence shows
Randomised trials examine specific authorised or investigational treatment regimens; STEP 1 and its extension answer different treatment-period and follow-up questions.
What remains uncertain
A trial average does not predict an individual result, and published medicine evidence cannot authenticate or validate a separately supplied preparation.
The basics
What is Semaglutide?
Semaglutide is an active substance in several prescription medicines. The MHRA identifies UK products with different licensed uses, including diabetes and weight management. The active-substance name should be read alongside the exact medicinal product and indication.
A product carrying the same ingredient name is not automatically equivalent to a licensed medicine. Authorisation concerns a defined product and its quality, safety and effectiveness for specified uses. It cannot be inferred from a research label, packaging photograph or an unrelated laboratory report.
Biological action
How does Semaglutide work?
Semaglutide acts at the glucagon-like peptide-1 receptor. GLP-1 signalling is involved in appetite, food intake and glucose regulation. This differs from tirzepatide's dual GIP/GLP-1 mechanism and retatrutide's investigational triple-receptor approach.
Counting receptor targets is not a way to rank clinical benefit. Different molecules must be evaluated using relevant clinical evidence, including measured outcomes and harms. More targets do not by themselves establish a better result for an individual.
Questions being investigated
What do studies examine?
Weight-management trials
STEP 1 evaluated semaglutide alongside lifestyle intervention in adults with overweight or obesity without diabetes. Its eligibility criteria and follow-up are essential to interpreting the result.
After treatment withdrawal
The STEP 1 extension followed a subset after the treatment period ended. It provides information about weight and cardiometabolic changes in that follow-up group.
Product and indication differences
Medicine-specific information identifies the licensed population, formulation and warnings. A finding for one study population should not be transferred automatically to every semaglutide product or use.
What individual studies found
Randomised, double-blind trial; 1,961 adults; 68 weeks
STEP 1: treatment-period evidence
Weight outcomes favoured semaglutide plus lifestyle intervention over placebo plus lifestyle intervention. Gastrointestinal events were reported, and some participants discontinued because of them.
How to read this: The finding belongs to this trial, its eligibility criteria and study intervention. It is not a guarantee of a particular personal outcome.
Read the original study ↗Exploratory follow-up of a subset after the main trial
STEP 1 extension: after withdrawal
The extension reported weight regain after withdrawal, with cardiometabolic measures tending back towards baseline.
How to read this: This addresses follow-up after treatment and lifestyle support stopped; it is not a new randomised comparison of stopping versus continuing therapy.
Read the original study ↗Strength of evidence
How strong is the evidence?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
| Evidence type | What it tells us |
|---|---|
| Laboratory | GLP-1 receptor activity provides a biological explanation; it does not replace outcome studies. |
| Animal | Preclinical evidence and human trials answer different questions and should be identified separately. |
| Human | Large randomised trials provide evidence for specific interventions in defined populations. Follow-up studies add context about durability and withdrawal. |
| Regulatory | Specific semaglutide medicines are authorised in the UK. They are prescription-only and require an appropriate clinical assessment and legitimate supply. |
Important context
Risks, limitations and unanswered questions
- STEP 1 excluded diabetes, so its result should not be presented as if all diabetes populations were studied.
- The extension concerned a subset and had a different design from the randomised treatment period.
- Gastrointestinal effects and other important warnings require the current medicine-specific information and clinical advice.
- This educational guide does not recommend starting, stopping or switching a medicine, and gives no administration instructions.
Reading the original evidence
Treatment-period and withdrawal findings are different
STEP 1 measured outcomes during treatment, while its extension followed a smaller subset after treatment and lifestyle support stopped. The extension describes that follow-up group; it does not prove that every participant or individual has the same experience.
Question to take to the source: Does the summary distinguish an on-treatment result from a result after withdrawal, including who remained in follow-up?
Check the original source ↗For personal accounts and research questionnaires, read user feedback and patient-reported outcomes.
Questions answered
Semaglutide FAQs
Is semaglutide the same as tirzepatide?
No. Semaglutide is a GLP-1 receptor agonist; tirzepatide activates GIP and GLP-1 receptors. Different receptor profiles do not by themselves establish which medicine is appropriate for an individual.
Does STEP 1 describe everyone using semaglutide?
No. It enrolled adults meeting specific criteria and excluded diabetes. Findings should be read with the population, intervention and follow-up clearly stated.
Does weight loss always persist after withdrawal?
The STEP 1 extension reported regain in its follow-up group. It does not establish a universal individual outcome or replace medical advice about ongoing treatment.
Does a semaglutide label prove that a product is authorised?
No. The ingredient name alone does not establish a product's identity, quality or licensed status. Consult official product information and a qualified prescriber or pharmacist.
Why should clinical results include adverse events?
Effectiveness and tolerability are separate parts of the evidence. A fair trial summary includes the outcomes measured, adverse findings and discontinuations rather than presenting benefits alone.
Check the sources
Sources and further reading
Follow the original study or official information to check the population, methods and full results. Reviews and sponsor updates are labelled below.
- Wilding et al. (2021): STEP 1 ↗Primary randomised clinical trial; adults with overweight or obesity without diabetes.
- Wilding et al. (2022): STEP 1 extension ↗Primary follow-up publication after withdrawal, involving a subset of the original trial.
- MHRA: GLP-1 medicines information ↗UK regulatory information about authorised products, prescription requirements and unregulated supply.
Educational information, prepared with AI assistance and not independently clinically reviewed. It is not personal medical advice or a treatment recommendation. Read the editorial policy or suggest a correction.